Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open, Dose-escalation, Multi-center, Phase 1 Trial to Evaluate Tolerability and Safety of Intramuscularly Administered BD03, a DNA Vaccine for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient

NCT03576014 is registered in ClinicalTrials.gov with SL VAXiGEN as lead sponsor.

NCT NCT03576014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open, Dose-escalation, Multi-center, Phase 1 Trial to Evaluate Tolerability and Safety of Intramuscularly Administered BD03, a DNA Vaccine for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient
Lead sponsor
SL VAXiGEN
Phase
Phase 1
Overall status
Unknown status
Start date
April 27, 2018
Completion date
July 24, 2019
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bk virus infection, cytomegalovirus infections, preventation of bk virus reactivation, preventation of cytomegalovirus reactivation